Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Significant correlation between peripheral blood CD34+ cell count in children prior to aphaeresis and CD34+ cell yield following aphaeresis: A single-center experience.

Rosenfeld-Keidar H, Eshel R, Pinhasov A, Bitan M, Edelman S, Broitman M, Dvir R, Sadot E, Levin D, Manisterski M, Berger-Achituv S, Elhasid R.

Pediatr Transplant. 2018 May;22(3):e13150. doi: 10.1111/petr.13150. Epub 2018 Mar 2.

PMID:
29498177
2.

Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.

Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J.

Biol Blood Marrow Transplant. 2018 Mar;24(3):521-528. doi: 10.1016/j.bbmt.2017.11.004. Epub 2017 Nov 16.

3.

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.

Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO, Wood WA, Savani BN, Kamble RT, Parsons S, Ahmed I, Sullivan K, Beattie S, Dandoy C, Munker R, Marino S, Bitan M, Abdel-Azim H, Aljurf M, Olsson RF, Joshi S, Buchbinder D, Eckrich MJ, Hashmi S, Lazarus H, Marks DI, Steinberg A, Saad A, Gergis U, Krishnamurti L, Abraham A, Rangarajan HG, Walters M, Lipscomb J, Saber W, Satwani P.

Haematologica. 2017 Nov;102(11):1823-1832. doi: 10.3324/haematol.2017.169581. Epub 2017 Aug 17.

4.

Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation.

Bitan M, Ahn KW, Millard HR, Pulsipher MA, Abdel-Azim H, Auletta JJ, Brown V, Chan KW, Diaz MA, Dietz A, Vincent MG, Guilcher G, Hale GA, Hayashi RJ, Keating A, Mehta P, Myers K, Page K, Prestidge T, Shah NN, Smith AR, Woolfrey A, Thiel E, Davies SM, Eapen M.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1523-1530. doi: 10.1016/j.bbmt.2017.05.011. Epub 2017 May 17.

5.

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.

Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, Savani BN, Akpek G, Aljurf M, Bajwa R, Baker KS, Beitinjaneh A, Bitan M, Buchbinder D, Chow E, Dandoy C, Dietz AC, Diller L, Gale RP, Hashmi SK, Hayashi RJ, Hematti P, Kamble RT, Kasow KA, Kletzel M, Lazarus HM, Malone AK, Marks DI, O'Brien TA, Olsson RF, Ringden O, Seo S, Steinberg A, Yu LC, Warwick A, Shaw B, Duncan C.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1327-1334. doi: 10.1016/j.bbmt.2017.04.017. Epub 2017 Apr 28.

6.

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS.

Bone Marrow Transplant. 2017 Mar;52(3):400-408. doi: 10.1038/bmt.2016.265. Epub 2016 Dec 12.

7.

Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.

Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ.

Haematologica. 2016 Oct;101(10):1267-1274. Epub 2016 May 31.

8.

Combined plerixafor and granulocyte colony-stimulating factor for harvesting high-dose hematopoietic stem cells: Possible niche for plerixafor use in pediatric patients.

Bitan M, Eshel R, Sadot E, Friedman S, Pinhasov A, Levin D, Dvir R, Manisterski M, Berger-Achituv S, Rosenfeld-Keidar H, Elhasid R.

Pediatr Transplant. 2016 Jun;20(4):565-71. doi: 10.1111/petr.12692. Epub 2016 Mar 16.

PMID:
26991903
9.

European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards.

Anthias C, O'Donnell PV, Kiefer DM, Yared J, Norkin M, Anderlini P, Savani BN, Diaz MA, Bitan M, Halter JP, Logan BR, Switzer GE, Pulsipher MA, Confer DL, Shaw BE.

Biol Blood Marrow Transplant. 2016 Mar;22(3):514-9. doi: 10.1016/j.bbmt.2015.11.009. Epub 2015 Nov 18.

10.

Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association.

Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, Shaw BE, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA.

Biol Blood Marrow Transplant. 2016 Jan;22(1):96-103. doi: 10.1016/j.bbmt.2015.08.017. Epub 2015 Aug 22. Review.

11.

Management of Acute Myeloblastic Leukemia in a Child With Biallelic Mismatch Repair Deficiency.

Elhasid R, Dvir R, Rosenfeld Keidar H, Ben Shachar S, Bitan M, Solar I, Durno C, Aronson M, Malkin D, Hawkins C, Bouffet E, Tabori U; BMMRD Consortium.

J Pediatr Hematol Oncol. 2015 Nov;37(8):e490-3. doi: 10.1097/MPH.0000000000000415.

PMID:
26274037
12.

Secondary solid cancer screening following hematopoietic cell transplantation.

Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS.

Bone Marrow Transplant. 2015 Aug;50(8):1013-23. doi: 10.1038/bmt.2015.63. Epub 2015 Mar 30. Review.

13.

Heparanase expression in Langerhans cell histiocytosis.

Dvir R, Vlodavsky I, Ilan N, Bitan M, Issacov J, Elhasid R.

Pediatr Blood Cancer. 2014 Oct;61(10):1883-5. doi: 10.1002/pbc.25046. Epub 2014 Apr 15.

PMID:
24737657
14.

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM.

Blood. 2014 Mar 6;123(10):1615-20. doi: 10.1182/blood-2013-10-535716. Epub 2014 Jan 16.

15.

Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.

Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C.

Blood. 2013 Nov 21;122(22):3651-8. doi: 10.1182/blood-2013-05-501510. Epub 2013 Aug 27.

16.

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.

Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA.

Bone Marrow Transplant. 2013 Aug;48(8):1056-64. doi: 10.1038/bmt.2012.284. Epub 2013 Feb 18.

17.

Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry.

Tamary H, Nishri D, Yacobovich J, Zilber R, Dgany O, Krasnov T, Aviner S, Stepensky P, Ravel-Vilk S, Bitan M, Kaplinsky C, Ben Barak A, Elhasid R, Kapelusnik J, Koren A, Levin C, Attias D, Laor R, Yaniv I, Rosenberg PS, Alter BP.

Haematologica. 2010 Aug;95(8):1300-7. doi: 10.3324/haematol.2009.018119. Epub 2010 Apr 30.

18.

Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Bitan M, Weiss L, Zeira M, Zcharia E, Slavin S, Nagler A, Vlodavsky I.

PLoS One. 2010 Apr 15;5(4):e10135. doi: 10.1371/journal.pone.0010135.

19.

Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.

Bitan M, Weiss L, Reibstein I, Zeira M, Fellig Y, Slavin S, Zcharia E, Nagler A, Vlodavsky I.

Mol Immunol. 2010 Jun;47(10):1890-8. doi: 10.1016/j.molimm.2010.03.014.

20.

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin.

Tsirigotis P, Shapira MY, Or R, Bitan M, Samuel S, Gesundheit B, Ackerstein A, Abdul-Hai A, Slavin S, Resnick IB.

Bone Marrow Transplant. 2010 Jul;45(7):1189-96. doi: 10.1038/bmt.2009.331. Epub 2009 Nov 30.

PMID:
19946341
21.

Oral effects of nonmyeloablative stem cell transplantation: a prospective observational study.

Elad S, Shapira MY, McNeal S, Or R, Garfunkel AA, Hirschhorn A, Bitan M, Resnick I, Benjamin G, Barasch A.

Quintessence Int. 2008 Sep;39(8):673-8.

PMID:
19107254
22.

Alefacept treatment for refractory chronic extensive GVHD.

Shapira MY, Abdul-Hai A, Resnick IB, Bitan M, Tsirigotis P, Aker M, Gesundheit B, Slavin S, Or R.

Bone Marrow Transplant. 2009 Feb;43(4):339-43. doi: 10.1038/bmt.2008.324. Epub 2008 Oct 13.

PMID:
18850020
23.

Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production.

Bitan M, Weiss L, Zeira M, Reich S, Pappo O, Vlodavsky I, Slavin S.

Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):413-21. doi: 10.1002/dmrr.868.

PMID:
18561210
24.

ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.

Resnick IB, Tsirigotis PD, Shapira MY, Aker M, Bitan M, Samuel S, Abdul-Hai A, Ackerstein A, Or R, Slavin S.

Biol Blood Marrow Transplant. 2008 Apr;14(4):409-17. doi: 10.1016/j.bbmt.2008.01.003.

25.

Oral posttransplantation lymphoproliferative disorder: an uncommon site for an uncommon disorder.

Elad S, Meyerowitz C, Shapira MY, Glick M, Bitan M, Amir G.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):59-64. Review.

PMID:
18155610
26.

Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes.

Tsirigotis P, Sella T, Shapira MY, Bitan M, Bloom A, Kiselgoff D, Levin M, Libster D, Abdul Hai A, Gesundheit B, Or R, Slavin S, Resnick I.

Haematologica. 2007 Nov;92(11):e106-10.

27.

Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia.

Bitan M, Or R, Shapira MY, Resnick IB, Gesundheit B, Ackerstein A, Samuel S, Elad S, Slavin S.

Bone Marrow Transplant. 2008 Jan;41(1):69-78. Epub 2007 Nov 12.

PMID:
17994125
28.

Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.

Resnick IB, Aker M, Tsirigotis P, Shapira MY, Abdul-Hai A, Bitan M, Gesundheit B, Amar A, Ackerstein A, Samuel S, Slavin S, Or R.

Bone Marrow Transplant. 2007 Nov;40(10):957-64. Epub 2007 Sep 10.

PMID:
17846604
29.

Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study.

Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M, Sacks Z, Shapira MY.

Transplantation. 2007 Mar 15;83(5):577-81.

PMID:
17353777
30.

A decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation.

Elad S, Thierer T, Bitan M, Shapira MY, Meyerowitz C.

Oral Oncol. 2008 Jan;44(1):37-42. Epub 2007 Feb 16.

PMID:
17307024
31.

Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.

Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A, Samuel S, Tsirigotis P, Gesundheit B, Slavin S, Shapira MY.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1295-301.

32.

A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.

Gesundheit B, Shapira MY, Ackerstein A, Resnik IB, Bitan M, Or R.

Acta Haematol. 2007;117(2):119-21. Epub 2006 Nov 29.

PMID:
17135719
33.

Epstein-Barr virus infection after stem cell transplantation: new concepts are needed both for the donor and the recipient.

Bitan M.

Clin Infect Dis. 2006 Oct 1;43(7):896-7. Epub 2006 Aug 28. No abstract available.

PMID:
16941372
34.

Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate.

Miodosky M, Abdul-Hai A, Tsirigotis P, Or R, Bitan M, Resnick IB, Gesundheit B, Zilberman I, Ioffe L, Leubovic A, Slavin S, Shapira MY.

Bone Marrow Transplant. 2006 Oct;38(7):507-11. Epub 2006 Aug 21.

PMID:
16921402
35.

Oral candidiasis prevention in transplantation patients: a comparative study.

Elad S, Wexler A, Garfunkel AA, Shapira MY, Bitan M, Or R.

Clin Transplant. 2006 May-Jun;20(3):318-24.

PMID:
16824148
36.

Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.

Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S.

Biol Blood Marrow Transplant. 2006 Jul;12(7):712-8.

37.

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S; Israel Glivec in Solid Tumors Study Group.

Endocr Relat Cancer. 2006 Jun;13(2):535-40.

PMID:
16728580
38.

Paving the way toward a better understanding of viral T cell interactions after stem cell transplantation.

Bitan M.

Clin Infect Dis. 2006 Jun 15;42(12):1749-50. Epub 2006 May 4. No abstract available.

PMID:
16705582
39.

Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.

Resnick IB, Aker M, Shapira MY, Tsirigotis PD, Bitan M, Abdul-Hai A, Samuel S, Ackerstein A, Gesundheit B, Zilberman I, Miron S, Yoffe L, Lvovich A, Slavin S, Or R.

Br J Haematol. 2006 Jun;133(6):649-54.

PMID:
16704442
40.

A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation.

Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B, Cohen Y, Diss O, Barak D, Dray L, Or R.

Bone Marrow Transplant. 2006 Apr;37(8):757-62.

PMID:
16518424
41.

Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.

Resnick IB, Abdul Hai A, Shapira MY, Bitan M, Hershkovitz E, Schwartz A, Ben-Harush M, Or R, Slavin S, Kapelushnik J.

Clin Transplant. 2005 Dec;19(6):840-7.

PMID:
16313334
42.

Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.

Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, Zilberman I, Miron S, Leubovic A, Slavin S, Or R.

Bone Marrow Transplant. 2005 Dec;36(12):1097-101.

PMID:
16247429
43.

Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.

Bitan M, Or R, Shapira MY, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S.

Haematologica. 2005 Aug;90(8):1089-95.

44.

Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells.

Bitan M, Shapira MY, Resnick IB, Zilberman I, Miron S, Samuel S, Ackerstein A, Elad S, Israel S, Amar A, Fibach E, Or R, Slavin S.

Exp Hematol. 2005 Jun;33(6):713-8.

PMID:
15911096
45.
46.

Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products.

Or R, Aker M, Shapira MY, Resnick I, Bitan M, Samuel S, Slavin S.

Springer Semin Immunopathol. 2004 Nov;26(1-2):133-42. Epub 2004 Sep 30. Review.

PMID:
15549305
47.

Spinal epidural lipomatosis following haploidentical allogeneic bone marrow transplantation for non-Hodgkin lymphoma.

Resnick IB, Gomori JM, Kiselgoff D, Lossos A, Zilberman I, Miron S, Bitan M, Or R, Slavin S, Shapira MY.

Clin Transplant. 2004 Dec;18(6):762-5.

PMID:
15516259
48.

Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.

Bitan M, Or R, Shapira MY, Mador N, Resnick IB, Saleh N, Weinberger KM, Samuel S, Schechter E, Slavin S, Wolf DG.

Clin Infect Dis. 2004 Oct 1;39(7):1076-8. Epub 2004 Sep 2.

PMID:
15472865
49.

Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.

Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R.

Clin Transpl. 2003:275-82. Review.

PMID:
15387119
50.

Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.

Shapira MY, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, Miron S, Zilberman I, Slavin S, Or R.

Bone Marrow Transplant. 2004 Jul;34(2):155-9.

PMID:
15235577

Supplemental Content

Support Center